WO2003092634A2 - Composition topique pour le traitement de tissu cicatriciel - Google Patents

Composition topique pour le traitement de tissu cicatriciel Download PDF

Info

Publication number
WO2003092634A2
WO2003092634A2 PCT/ZA2003/000059 ZA0300059W WO03092634A2 WO 2003092634 A2 WO2003092634 A2 WO 2003092634A2 ZA 0300059 W ZA0300059 W ZA 0300059W WO 03092634 A2 WO03092634 A2 WO 03092634A2
Authority
WO
WIPO (PCT)
Prior art keywords
percentage
mass
composition
topical
topical composition
Prior art date
Application number
PCT/ZA2003/000059
Other languages
English (en)
Other versions
WO2003092634A3 (fr
Inventor
Leslie Peter Mckenzie
Original Assignee
Engelbrecht, Edna
Jackson, Berdine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engelbrecht, Edna, Jackson, Berdine filed Critical Engelbrecht, Edna
Priority to AU2003252185A priority Critical patent/AU2003252185A1/en
Publication of WO2003092634A2 publication Critical patent/WO2003092634A2/fr
Publication of WO2003092634A3 publication Critical patent/WO2003092634A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Definitions

  • This invention is in the field of topical compositions, specifically those used in the treatment of and for the prevention of the formation of scar tissue of the skin.
  • the normal healing process of the skin involves the activation and formation of connective tissue.
  • the treatment of unsightly keloid is either surgical removal, radiation at the beginning of the healing process, laser or topical compositions that improve the skins healing properties and diminish already existing scar tissue.
  • Abnormal scar tissue formation can therefore be prevented by controlling the fibroblastic reaction and in the case where the scar has already formed, by softening and normalizing the keloid.
  • a topical cosmetic composition which includes Butylated Hydroxy Toluene, Marula Oil, Alpha Tocopherol Acetate, Vitamin A Palmitate, Tea Tree Oil, Propyl-p- hydroxybenzoate, Pteroyl Glutamic Acid, collagen, Placentol, Liposome Complex, Methyl-p-hydroxybenzoate, and Dextropantothenyl Alcohol.
  • the composition includes Encapsulated Tea Tree Oil.
  • composition may include Glyceril Stearate.
  • composition may include Ceteareth-12.
  • composition may include Ceteareth-20.
  • composition may include Cetiol SB 45.
  • composition may include Emulgate CL.
  • composition may include Carbomer.
  • composition may include an 8.33% solution of Triethanolamine 85%.
  • composition may include lavender fragrance.
  • the composition may include distilled water.
  • the composition may include Glyceril Stearate, Ceteareth-12, Ceteareth-20, Cetiol SB 45, Emulgate CL, Carboner 934, 8.33 % Triethanolamine 85% solution, lavender fragrance, and distilled water.
  • the composition may be a mixture of an oil phase and a water phase.
  • the percentage by mass of the Glyceril Stearate may be from 0 to 10%
  • the percentage by mass of the Ceteareth-12 may be from 0 to 10%
  • the percentage by mass of the Ceteareth-20 may be from 0 to 10%
  • the percentage by mass of the Butyrospermum Parrii may be from 0 to 10%
  • the percentage by mass of the Butylated Hydroxyl Toluene may be from 0.01 to 1%
  • the percentage by mass of the Marula Oil may be from 5 to 15%
  • the percentage by mass of the Alpha Tocopheral Acetate may be from 1 to 20%
  • Vitamin A Palmitate may be from 0.05 to 5%, the percentage by mass of
  • Emulgate CL may be from 0 to 2%, the percentage by mass of the Tea Tree Oil may be from 1 to 5%, the percentage by mass of Propyl-p-hydroxybenzoate may be from 0.05 to 5%, the percentage by mass of the encapsulated tea tree oil may be from 0.01 to 1%.
  • the percentage by mass of the Pteroyl Glutamic Acid may be from 0.01 to 5%
  • the percentage by mass of the Carbomer may be from 0.1 to 5%
  • the percentage by mass of the collagen may be from 1 to 10%
  • the percentage by mass of the Placentol may be from 1 to 10%
  • the percentage by mass of the Liposome Complex may be from 1 to 10%
  • the percentage by mass of the Methyl-p-hydroxybenzoate may be from 0.1 to 2%
  • the percentage by mass of the Triethanolamine 85% 8.33% solution may be from 1 to 10%
  • the percentage by mass of the Dextropantothenyl Alcohol may be from 1 to 10%
  • the percentage by mass of the lavender fragrance may be from 0.1 to 2%
  • the percentage by mass of the distilled water may be from 40 to 50%.
  • the topical composition may be in the form of a cream where in the oil phase the percentage by mass of the Glyceril Stearate is 6%, the percentage by mass of the Ceteareth-12 is 2%, the percentage by mass of the Ceteareth-20 is 2%, the percentage by mass of the Butyrospermum Parrii is 5%, the percentage by mass of the Butylated Hydroxyl Toluene is 0.01%, the percentage by mass of the Marula Oil is 9%, the percentage by mass of the Alpha Tocopheral Acetate is 1%, the percentage by mass of the Vitamin A Palmitate is 0.4%, the percentage by mass of the Emulgate CL is 2%, the percentage by mass of the Tea Tree Oil is 1 %, the percentage by mass of the Nipasol M is 0.015%), the percentage by mass of the encapsulated tea tree oil is 1%, the percentage by mass of the Pteroyl Glutamic Acid is 1%, the percentage by mass of the Carbomer is 0.45%, the percentage by mass of the
  • the topical medical composition may be in the form of a lotion.
  • topical medical composition may be in the form of an oil.
  • a method of treating or inhibiting the formation of scar tissue on the skin of a person including the periodic topical application of a composition as described above to the skin of the person in the vicinity of a wound or a scar.
  • composition may be applied in a thin layer to the wound or scar and surrounding skin at least once a day for a period of at least a week.
  • the composition may be applied two or more times a day.
  • the composition may be applied for 28 days.
  • composition may be applied for any period.
  • the topical composition may be prepared from the oil phase and the water phase as set out below and as shown in Table 1.
  • the following method was one method which was found to result in a useable topical composition.
  • a cream prepared in accordance with the invention was used by a plastic surgeon in the following clinical situations: 1. Hypertrophic scarring
  • Table 2 Identification of components by trade name and INCI name.
  • NB JCIC: JAPANESE COSMETIC INGREDIENT CODEX

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition topique qui comprend au moins du butyl hydroxytoluène, de l'huile de marula, de l'acétate de l'alpha tocophérol, du palmitate de vitamine A, de l'huile de théier, du p-hydroxybenzoate de propyle, de l'acide ptéroylglutamique, du collagène, du placentol, un complexe liposomique, du p-hydroxybenzoate de méthyle et de l'alcool dextropantothénylique. L'invention concerne également un procédé permettant de traiter un tissu cicatriciel ou d'inhiber la formation de tissu cicatriciel, ce procédé consistant à appliquer de façon topique et périodique la composition susmentionnée sur la peau de la personne, proche d'une blessure ou d'une cicatrice.
PCT/ZA2003/000059 2002-05-06 2003-05-06 Composition topique pour le traitement de tissu cicatriciel WO2003092634A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003252185A AU2003252185A1 (en) 2002-05-06 2003-05-06 Topical composition for the treatment of scar tissue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA02/3555 2002-05-06
ZA200203555 2002-05-06

Publications (2)

Publication Number Publication Date
WO2003092634A2 true WO2003092634A2 (fr) 2003-11-13
WO2003092634A3 WO2003092634A3 (fr) 2004-04-01

Family

ID=29401968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2003/000059 WO2003092634A2 (fr) 2002-05-06 2003-05-06 Composition topique pour le traitement de tissu cicatriciel

Country Status (2)

Country Link
AU (1) AU2003252185A1 (fr)
WO (1) WO2003092634A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883003A1 (fr) * 2005-03-14 2006-09-15 Aldivia Sa Nouveaux antioxydants a base d'especes d'anacardiacees, plus particulierement de sclerocarya birrea, leurs procedes d'obtention et leurs applications
CN100459972C (zh) * 2006-11-07 2009-02-11 华南农业大学 一种祛痘润肤乳及其制备方法
US8445040B2 (en) 2008-02-19 2013-05-21 Management and Holdings—Ardom Extracts of Sclerocarya birrea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384125A (en) * 1987-03-31 1995-01-24 Water-Jel Technologies, Inc. Burn dressing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA781899B (en) * 1978-04-04 1979-12-27 A Beer Geneeskundige middel en metode van bereiding
JP3057207B2 (ja) * 1991-09-03 2000-06-26 株式会社資生堂 皮膚外用剤
CN1085436A (zh) * 1992-10-05 1994-04-20 王春华 烧烫伤药的制作方法
ZA9811105B (en) * 1998-12-04 1999-08-25 Leslie Peter Mckenzie Cosmetic and pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384125A (en) * 1987-03-31 1995-01-24 Water-Jel Technologies, Inc. Burn dressing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 198013 Derwent Publications Ltd., London, GB; Class B04, AN 1980-23739C XP002258347 & ZA 7 801 899 A (DE BEER A C) 27 December 1979 (1979-12-27) *
DATABASE WPI Section Ch, Week 199412 Derwent Publications Ltd., London, GB; Class B04, AN 1994-097768 XP002258348 & JP 06 048929 A (SHISEIDO CO LTD) 22 February 1994 (1994-02-22) *
DATABASE WPI Section Ch, Week 199527 Derwent Publications Ltd., London, GB; Class B04, AN 1995-201006 XP002258346 & CN 1 085 436 A (WANG C) 20 April 1994 (1994-04-20) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883003A1 (fr) * 2005-03-14 2006-09-15 Aldivia Sa Nouveaux antioxydants a base d'especes d'anacardiacees, plus particulierement de sclerocarya birrea, leurs procedes d'obtention et leurs applications
WO2006097806A1 (fr) * 2005-03-14 2006-09-21 Aldivia Antioxydants a base d'especes d'anacardiacees, leurs procedes d'obtention et leurs applications
CN100459972C (zh) * 2006-11-07 2009-02-11 华南农业大学 一种祛痘润肤乳及其制备方法
US8445040B2 (en) 2008-02-19 2013-05-21 Management and Holdings—Ardom Extracts of Sclerocarya birrea

Also Published As

Publication number Publication date
AU2003252185A8 (en) 2003-11-17
WO2003092634A3 (fr) 2004-04-01
AU2003252185A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
TWI286941B (en) Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
US20210228467A1 (en) High-Potency Vitamin C Topical Formulations
CN107281185B (zh) 一种促进毛发生长的乳化组合物及其制备方法
CN1337269A (zh) 皮肤的局部疗法
CA2528431A1 (fr) Traitement et prevention des exces cicatriciels au moyen de tamoxifene 4-hydroxy
CN104994911A (zh) 包括二十碳五烯酸游离酸和γ-亚麻酸游离酸的化妆品组合物及其制造和使用方法
WO2003092634A2 (fr) Composition topique pour le traitement de tissu cicatriciel
JP4681132B2 (ja) 一酸化窒素合成酵素産生促進剤および化粧料若しくは医薬組成物
JPH10251133A (ja) 皮膚外用剤
JPS6267028A (ja) 肌荒れ防止剤
JPH04198131A (ja) 創傷治癒促進剤およびそれを含有する外用組成物
ZA200409807B (en) Topical composition for the treatment of scar tissue.
KR20090113614A (ko) 레티놀 유도체를 함유하는 화장료 조성물
EP3573621B1 (fr) Dérivés de glycopeptides destinés à être utilisés dans le traitement et/ou la prévention et/ou l'atténuation de maladies de fibrose
WO2002089826A1 (fr) Procede de preparation d'un onguent a base d'ail et composition d'onguent a base d'ail pour l'utilisation topique en cas d'infection cutanee
JP2001206813A (ja) 物理的治療用の皮膚外用剤
JP2003321463A (ja) 皮膚外用剤
AU668986B2 (en) Topical composition
RU2788332C1 (ru) Мазь для лечения травматического повреждения кожных покровов
JP6981675B2 (ja) 頭皮外用剤と、活性酸素消去作用とカルボニルタンパク生成抑制作用を制御する方法
KR102215013B1 (ko) 피토스핑고신 및 지방산을 포함하는 구형 결정 구조체 조성물 및 그 제조방법
AU2021103389A4 (en) A Skincare Serum
JP2012254957A (ja) 皮膚外用剤およびその製造方法
JP2829157B2 (ja) 皮膚外用剤
WO2003097100A1 (fr) Composition topique de traitement d'etats inflammatoires de la peau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200409807

Country of ref document: ZA

Ref document number: 2004/09807

Country of ref document: ZA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP